Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245723 | 1.00 | TSHR (0.44) | TSHRPTPN1 | |
| SCHEMBL27944429 | 0.93 | TSHR (0.42) | TSHRPTPN1 | |
| SCHEMBL14561024 | 0.85 | — | — | |
| SCHEMBL27684310 | 0.84 | PTPN1 (0.41) | PTPN1 | |
| SCHEMBL1245695 | 0.84 | ALDH1A1 (0.43) | PTPN1 | |
| SCHEMBL24046835 | 0.84 | ALDH1A1 (0.43) | PTPN1 | |
| SCHEMBL1866665 | 0.84 | ALDH1A1 (0.43) | PTPN1 | |
| SCHEMBL116734 | 0.84 | ALDH1A1 (0.43) | PTPN1 | |
| SCHEMBL1296286 | 0.81 | PTPN1 (0.34) | PTPN1 | |
| SCHEMBL1453540 | 0.81 | PTPN1 (0.34) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509647-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | The Procter and Gamble Company (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2018048852-A1 | ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS | THE PROCTER & GAMBLE COMPANY (US) | 2018-03-15 | — | — | WO | claimed |
| EP-3509562-A1 | AEROSOL COMPOSITIONS | The Procter and Gamble Company (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3509705-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS | The Procter and Gamble Company (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3509561-A1 | PERFUME COMPOSITIONS | The Procter and Gamble Company (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018048717-A1 | PERFUME COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018048718-A1 | AEROSOL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018048719-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2018-03-15 | — | — | WO | disclosed |
| US-7893268-B2 | Epithiolone analogues | UNIVERSITY OF TOLEDO (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893268-B2 | Epithiolone analogues | UNIVERSITY OF TOLEDO (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090258904-A1 | Epithiolone Analogues | UNIVERSITY OF TOLEDO | 2009-10-15 | — | — | US | disclosed |
| US-20090258904-A1 | Epithiolone Analogues | UNIVERSITY OF TOLEDO | 2009-10-15 | — | — | US | disclosed |
| WO-2007015929-A2 | EPOTHILONE ANALOGUES | UNIVERSITY OF TOLEDO (US) | 2007-02-08 | — | — | WO | disclosed |
| US-6156905-A | Deoxy epothilones and intermediates utilized in the process for preparing epothilones | NOVARTIS AG (CH) | 2000-12-05 | — | — | US | disclosed |
| US-6043372-A | USEFUL CHEMICAL INTERMEDIATES FOR ANTICARCINOGENIC EPITHILONES | NOVARTIS AG (CH) | 2000-03-28 | — | — | US | disclosed |
| US-5969145-A | Process for the production of epothilones and intermediate products within the process | NOVARTIS AG (CH) | 1999-10-19 | — | — | US | disclosed |
| EP-0923583-A1 | METHOD FOR PRODUCING EPOTHILONES, AND INTERMEDIATE PRODUCTS OBTAINED DURING THE PRODUCTION PROCESS | Novartis AG (CH) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008849-A1 | METHOD FOR PRODUCING EPOTHILONES, AND INTERMEDIATE PRODUCTS OBTAINED DURING THE PRODUCTION PROCESS | NOVARTIS AKTIENGESELLSCHAFT (CH) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258904-A1 | Epithiolone Analogues | ESRRB, ESR2, ESRRA | TSHR 2808/4885PTPN1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.